Prostate Cancer Specialist Nursing Program: A Social Return on Investment
Moderator
Kim Edmunds, PhD, University of Queensland, Centre for the Business and Economics of Health, St Lucia, Australia
OBJECTIVES: While provision of cancer supportive care services for prostate cancer (PCa) patients during and after treatment have demonstrated efficacy in mitigating consequences of the disease, there is a lack of robust economic evidence regarding the benefits of such services. The aim of this economic evaluation was to assess the value for money of the Prostate Cancer Foundation of Australia (PCFA) Prostate Cancer Specialist Nursing (PCSN) and Telenursing programs.
METHODS: Social Return on Investment (SROI) framework was used to develop the economic model for the PCSN programs. Stakeholder consultations were conducted with the PCSN team to collect costs and generate the benefits associated with delivery of the PCSN program, supplemented with published evidence. Intangible benefits were also reported. Calculation of impact included dead weight loss, attribution, benefit time frame and discounting. Sensitivity analyses were conducted to test the robustness of the model.
RESULTS: Costs of the program (including costs of referral to other services) and seven major benefits were included in the final analysis: 1. Improved health related quality of life (HRQoL); 2. Reduced emergency department (ED) presentations and hospitalisations; 3. Reduced travel costs; 4. Reduced productivity losses; 5. Reductions in clinical consulting time; 6. Reductions in nurse coordination time; and 7. Reductions in missed appointments. The net present value and SROI for each program and a combined result are: PCSN program - NPV $14,633,133, SROI 1.62; Telenursing program - NPV $1,369,703, SROI 2.34; Combined - NPV $16, 003487, SROI 1.65.
CONCLUSIONS: A conservative SROI analysis was conducted and a strong positive return on investment demonstrated the successful implementation of the program. A qualitative assessment of intangible benefits for patients and healthcare providers showed high levels of satisfaction amongst all stakeholders and the reach of PCSNs across all six PCa survivorship domains. Impact: Australian government invested a further $35.4million over four years to 2026-27.
METHODS: Social Return on Investment (SROI) framework was used to develop the economic model for the PCSN programs. Stakeholder consultations were conducted with the PCSN team to collect costs and generate the benefits associated with delivery of the PCSN program, supplemented with published evidence. Intangible benefits were also reported. Calculation of impact included dead weight loss, attribution, benefit time frame and discounting. Sensitivity analyses were conducted to test the robustness of the model.
RESULTS: Costs of the program (including costs of referral to other services) and seven major benefits were included in the final analysis: 1. Improved health related quality of life (HRQoL); 2. Reduced emergency department (ED) presentations and hospitalisations; 3. Reduced travel costs; 4. Reduced productivity losses; 5. Reductions in clinical consulting time; 6. Reductions in nurse coordination time; and 7. Reductions in missed appointments. The net present value and SROI for each program and a combined result are: PCSN program - NPV $14,633,133, SROI 1.62; Telenursing program - NPV $1,369,703, SROI 2.34; Combined - NPV $16, 003487, SROI 1.65.
CONCLUSIONS: A conservative SROI analysis was conducted and a strong positive return on investment demonstrated the successful implementation of the program. A qualitative assessment of intangible benefits for patients and healthcare providers showed high levels of satisfaction amongst all stakeholders and the reach of PCSNs across all six PCa survivorship domains. Impact: Australian government invested a further $35.4million over four years to 2026-27.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE57
Topic
Economic Evaluation
Disease
SDC: Oncology, STA: Multiple/Other Specialized Treatments